KRAS and idiopathic pulmonary fibrosis: In an older study with highly selected patients with smoking-related IPF, the prevalence of driver mutations in EGFR and KRAS was 14.1% and 37.5%, respectively, showing consistency for the high KRAS mutation rates with the studies of [103,104], and the aforementioned studies by Honda et al. and Fujimoto et al. [105,106].